T 2011/21 - Incorrect video inspection of a device

Key points

• "the opposition division found that [auxiliary request 1] met the requirements of Article 83, 84 and 123(2) EPC and that the subject-matter of independent claim 1 was novel and involved an inventive step in view, among others, of the public prior use represented by the child safety seat commercialized with the name "Sirona" (bundle of evidence M11). During the oral proceedings which was held by videoconference the "Sirona" child safety seat was inspected remotely by the opposition division. The inspection was transmitted by videoconference to all parties with every party having been given the chance to direct the camera used for inspection to specific details of interest. Screenshots showing several relevant views and constructional details of the child safety seat "Sirona" were taken and attached to the protocol of inspection."
  
  
• "The public availability of the prior use of the "Sirona" child safety seat is not contested by the respondent (patent proprietor). Based on the taking of evidence, the opposition division concluded that the subject-matter of claim 1 according to the auxiliary request 1 underlying the decision under appeal was novel over this public prior use. The opposition division held that the inspected "Sirona" child safety seat did not comprise the feature introduced in claim 1 of the auxiliary request 1 that:

  "the outer shell (2) comprises a side wing (13) and the housing component (7) is embedded into the side wing (13)".  ... The conclusion of the opposition division regarding the alleged distinguishing feature above was based on an interpretation of the term "side wing" [...] which was considered too narrow by the appellant (opponent)." The Board agrees with the opponent.

• "In view of all the above and contrary to the findings of the opposition division, the subject-matter of claim 1 of the patent as maintained lacks novelty over the public prior use "Sirona". An assessment of the further novelty attacks raised by the appellant (opponent) is thus not required."

• Auxiliary request 3 is considered to be novel and inventive.

• In connectio with the opponent's request for reimbursement of the appeal fee: "the appellant (opponent) contested the correctness of the decision of the opposition division to hold oral proceedings and to carry out the inspection of the child safety seat "Sirona" per videoconference hence in the physical absence of the opposition division and of the parties although it had been requested to hold them in person. The appellant (opponent) essentially pointed out that in view of the complexity of the structure and design of the outer shell, in particular of the rear part of the "Sirona" child safety seat, it was not possible by a mere video-inspection to correctly identify the effective location/extension of the portions of the seat functionally corresponding to the "side wings" recited in claim 1.  

• "The Board considers that the opposition division erred in not granting the opponent's request to take evidence by inspection be made in-presence. The opponent's request was namely substantiated and in the Board's view well-founded, in particular because the object to be inspected was a complex three-dimensional item, and it could not a priori be ruled out that the images on the screen would allow the participants to appreciate the full extent of the disclosure."

• However, the Board considers the procedural error to be harmless because in the end the OD only found the claim to  be novel based on an issue claim interpretation. Hence the opponent was not adversely affected by the procedural decision of the OD.

EPO 

The link to the decision and an extract of it can be found after the jump.

T 0314/20 - Interpreting G 2/21

Key points

• This decision was issued in writing on 20.12.2024.  The decision was taken on 16.11.2023 (!). 
• No communication under Art. 15(9) RPB is visible in the public online file. We must trust the President of the Boards was informed of the delay as prescribed.
• The catchword is "On the interpretation of decision G 2/21 ",  so I can see why the Board needed some time.
• Claimed is the combination of empagliflozin with linagliptin. 
• "In support of the alleged  [technical effect of] "increase in GLP-1", the respondent [proprietor] referred to post-published documents D55 and D56."
• "As explained below, the technical effect relied on by the respondent for inventive step (see point 6.9 above) and possibly shown by document D56 cannot be taken into account for formulating the objective technical problem in light of decision G 2/21 "
• "he current Board identifies three challenges in interpreting point 2 of the order of decision G 2/21."
• "First, the requirements "encompassed by the technical teaching" and "embodied by the same originally disclosed invention" were not used in the plausibility case law underlying questions 2 or 3 of the referral. Therefore, their relation to this case law remains to be defined, particularly in terms of whether, and to what extent, they replace, align with, or modify it."
• "Second, the Enlarged Board did not expressly define these requirements. It could be argued that the dependent clause "because such an effect does not change the nature of the claimed invention" in point 93 of decision G 2/21 (see point 6.12.2 above) serves as their definition. However, if this were the case, it would be unclear why the Enlarged Board did not simply state that a patent applicant or proprietor can only rely on a technical effect if such an effect does not change the nature of the claimed invention, instead of introducing two distinct requirements. "
• "Finally, the Enlarged Board did not expressly state the purpose of these requirements."
  
  
• " In decision T 116/18 [of July 2023, after the remittal], the competent [Technical] Board reached a number of conclusions on the relationship, the purpose and the content of the two requirements outlined in point 2 of the order of decision G 2/21."
• See my blog post on that decision.
• " This Board faces two issues with the interpretation of decision G 2/21 given in the passages quoted from decision T 116/18 in point 6.13.4 above. [...]
• "the [TBA in T116/18 of July 2023] effectively adopted what it defined in the referral T 116/18 as the "ab initio implausibility" standard."
• "some of the inferences drawn in the passages quoted above from decision T 116/18 are not supported by the text of decision G 2/21. "
  
  
• "In the present case, the current Board does not need to give a definitive answer as to whether it can endorse all the conclusions of decision T 116/18 regarding the two requirements set out in point 2 of the order of decision G 2/21. The Board considers that the purpose of these requirements is to prevent patents from being granted for inventions that are not complete at the filing date. Such speculative applications arise where either the existence of the claimed technical effect or its generalisation is speculative. This may occur because relevant data have not yet been generated or, if available to the patent applicant, have not been disclosed in the patent application.
• " If the Board's understanding of the purpose of the two requirements - which aligns with the view in T 116/18 - is correct, the respondent cannot rely on the technical effect in this case. This is because a skilled person would not expect the technical effect in question - an increase in active GLP-1 levels from the combination of empagliflozin and linagliptin compared to increases in active GLP-1 levels achieved with combinations of emplagliflozin with sitagliptin and vildagliptin, respectively - on the basis of the original disclosure of the application itself. This effect is not only unsupported and not made credible by the application as originally filed; it even contradicts its technical teaching. Therefore, whatever the meaning of the two requirements in G 2/21, they cannot be met in the present case if patenting for inventions not made at the filing date is to be excluded."
  
  
• "as observed by the appellants [opponents] at the oral proceedings, the application as originally filed presents combinations of empagliflozin with linagliptin, sitagliptin, vildagliptin, saxagliptin or alogliptin at an equal level of preference. This is apparent from the paragraph directly below Table 1 (see page 33, lines 2 to 5). This paragraph explains that among the 176 combinations exemplified in Table 1, the combinations numbered "97", "165", "166", "167" and "168" are most preferred. Combination 97 pertains to the currently claimed combinations, i.e. combinations of empagliflozin and linagliptin or a pharmaceutically acceptable salt of it []. Combinations 165 to 168 relate to combinations of empagliflozin with sitagliptin, vildagliptin, saxagliptin and alogliptin, respectively []"
• "the purported technical effect relied upon by the respondent [proprietor] for inventive step is an increase in plasma levels of active GLP-1 which is stronger and more prolonged in time than the one achieved by combinations 165 and 166, i.e. combinations of empagliflozin with sitagliptin and vildagliptin, respectively (see point 6.9 above)."
• The Board states it like this. It is not entirely clear to me what D2, the closest prior art, discloses. 
• "The Board concludes that the technical teaching of the claimed invention that the skilled person, with the common general knowledge in mind, understands at the filing date from the application as originally filed, encompasses the following.

  (a) Combination 97 (i.e. the currently claimed combinations) gives rise, inter alia, to an increase in plasma levels of active GLP-1 in patients with metabolic disorders and related diseases.  (b) Combinations 165 to 168 (i.e. combinations of empagliflozin with sitagliptin, vildagliptin, alogliptin and saxagliptin, respectively), having the same level of preference, achieve the same increase in plasma levels of active GLP-1 in patients with metabolic disorders and related diseases as combination 97."

• "It follows from the analysis made in points 6.20 to 6.24 above that the skilled person, having the common general knowledge in mind, and based on the application as originally filed, would not derive the increase in plasma levels of active GLP-1 relied on by the respondent (see point 6.25 above) as being encompassed by the technical teaching of the claimed invention and embodied by the same originally disclosed invention."

• "From the above it follows that the objective technical problem is to provide a specific combination of a glucopyranosyl-substituted benzene derivative of formula I as shown in document D2 with a DPP IV inhibitor in the context of diabetic diseases."

• "In the board's judgement, the proposed solution would have been obvious having regard to the state of the art. The reasons are as follows."

• "In such cases of arbitrary selections, the prior art does not need to contain a pointer towards the compounds claimed, i.e. empagliflozin and linagliptin.  Instead, all possible solutions have to be regarded as being equally suitable and obvious candidates for solving the objective technical problem as defined above "

• The request for a referral to the Enlarged Board is refused. "in the case at hand, the Board also believes that any tenable interpretation of the requirements introduced in decision G 2/21 would lead to the conclusion that the respondent cannot rely on the alleged "increase in GLP-1" of the claimed combination"

• To cite a few more paragraphs: 

• "Irrespective of how the term "technical effect" in point 2 of the order of decision G 2/21 is to be interpreted, it remains that the technical effect relied upon by the respondent for acknowledgement of inventive step rests on experimental data (i.e. document D56, Figures 1 to 3 and Table 1) which does not confirm the technical teaching conveyed by the application as originally filed (i.e. the same increase in active plasma levels of active GLP-1 for combinations 97, 165 and 166). Rather, these experimental data teach against it. "

•  As regards the respondent's argument that the technical effect relied on did not change the nature of the claimed invention since the claimed combination was disclosed in the application as originally filed and no additions or changes to this combination were required to arrive at this effect, the Board notes that this is not sufficient for the requirements stated in point 2 of the order of G 2/21 to be met. More precisely, it is not enough that the claimed invention is disclosed in the application as originally filed in terms of its technical features and that these same features (possibly) achieve this effect without requiring any modification. Rather, it is the purported technical effect relied on for inventive step that must be derivable by the skilled person, having the common general knowledge in mind, and based on the application as originally filed, as being encompassed by the technical teaching and embodied by the same originally disclosed invention. These requirements are not met in the case at issue. "" 

• "For the reasons set out above, the technical effect "increase in GLP-1" associated specifically with the combination claimed would be unexpected to the skilled person in view of the application as originally filed. As a consequence, the alleged "increase in GLP-1" relied upon by the respondent for acknowledgement of inventive step cannot be taken into account for the formulation of the objective technical problem."

EPO 

R 0012/20 - Length of procedure

Key points

• The petition for review was filed by the opponent on 21.08.2020. The Enlarged Board, in a three-member panel, decided on the petition during oral proceedings of 19.07.2024. The decision was issued in writing on 07.10.2024.
• The OD had revoked the patent for insufficient disclosure. The TBA  reversed and remitted the case. The OD took a new decision in September 2022, i.e. two years  (!) after the petition for review was filed.  The OD rejected the opposition. The opponent did not appeal. 
• The EBA panel concludes that the petition is now moot, in translation: "No appeal was filed against this decision within the appeal period, so the parties were notified by communication dated 3 January 2023 that the patent was maintained in unchanged form and that the opposition proceedings had been concluded. The decision of the Opposition Division of 12 September 2022 thus has final effect."
• "The Enlarged Board of Appeal therefore concludes that the applicant can no longer rely on a continuing interest in bringing proceedings and that the admissibility requirements of the originally filed application for review are therefore no longer met."
• As a comment, perhaps there was no ground for appealing given that the TBA's findings in the first decision were still res iudicata. 
• According to the EBA, the opponent/petitioner is to blame ("has contributed on its own responsibility ", original "eigenverantwortlich dazu beigetragen, dass"): "By refraining from filing an appeal against the decision of the opposition division of 12 September 2022, at least as a precautionary measure, the applicant has contributed procedurally on its own responsibility not only to ensuring that this decision becomes final, but also to ensuring that the patent in dispute becomes final."
  
  
• I do not readily see how the finality of the decision / the patent in this case can be "larger" than in the case the Board had not remitted, i.e., reversed and simultaneously rejected the opposition in the appeal decision. I understand that in such a scenario, a petition for review does provide a remedy in case of one of the specified procedural defects. 
• 
  
• The panel of the EBA does not comment on the length of the procedure before it in the three-member panel composition. Should the EBA panel have managed to decide on the case in two years, there would have been no problem. 
• The first action of the EBA appears to be a communication of 13.12.2023, suggesting that the EBA did not process the petition for review  for a period of more than three years.
•  
• To cite the Explanatory Remarks to the EPC 2000, Article 112a EPC, from OJ 2007 Special Edition 4 (link): 
• 12. "The possibility of filing a petition for review must not cause long-lasting legal uncertainty for third parties. "
• 18. "In the interest of a quick and effective screening of petitions for review which are clearly inadmissible or not allowable, special procedural provisions apply to the three-member panel of the Enlarged Board established under Article 22(2), second sentence, and Rule 109(2) EPC 2000 (see explanatory remark n° 4 to Article 22 EPC). "
• "The proceedings before this panel shall be as simple and short as possible."
• "Therefore, this body shall decide in written summary proceedings without the involvement of other parties and on the basis of the petition (see Rule 109(3) EPC 2000). A quick screening procedure at the outset of review proceedings to sort out petitions which clearly cannot be successful is essential in order to avoid an inappropriate prolongation of legal uncertainty for third parties. It is also of great importance to counteract effectively intentional prolongation of proceedings by filing a petition for review."
• It seems the legislator did not even consider a scenario wherein the procedure before the three-member panel of the EBA would take so long as to become moot. 
• The EBA panel adds observations stating that the petition is clearly not allowable anyway. I understand these observations to be obiter and will not comment on them here: they should not distract from the procedural approach taken by the EBA panel. 
• To be clear: I'm not convinced that a petition for review can become moot because of the EBA's inaction in the way proposed by the EBA panel in this decision. Should the holding of the EBA panel in this case become established case law, it seems to me that it then will be even more important for the EBA panels that hear petition of review cases to avoid undue delay of the proceedings than it is now. 

EPO 

The link to the decision and an extract of it can be found after the jump.

T 1553/22 - Human-pig chimeras

Key points

• "Claims 3 [] of auxiliary request 2 read as follows: "3. A chimeric non-human blastocyst expressing human ETV2 and lacking expression of said non-human animal ETV2, wherein the blastocyst is porcine."
• "The application concerns the generation of pig-human chimeric animals with the aim of using them as a source of human vasculature and blood. The chimeric pigs are obtained by methods involving "blastocyst complementation". This involves creating a non-human (host) blastocyst lacking one or more genes involved in the development of the cells of interest. This creates a so-called "niche" which is complemented by introducing into the blastocyst human pluripotent (donor) cells having those lacking genes. Specifically, in the application, the host blastocyst lacks the Etv2 gene, whose function is to promote hematoendothelial development"
• " claims 3 and 4 do not include language that would exclude chimeras having human cell participation in the brain or germ cells."
• The applicant is a university.
• "In the appealed decision, the examining division refused the application for ethical reasons pursuant to Article 53(a) in conjunction with Rule 26(1) EPC and Recital 38 of the Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions (point 4.16 of the Reasons). "
• The Board: " The ethical dimension of patent law has found its expression in Article 53(a) EPC, together with the implementing regulations in Rules 26 to 29 EPC. These Rules were introduced in the EPC to align the EPC with the Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions (the "EU Biotech Directive"). In order to achieve harmonised protection in the field of biotechnological inventions in Europe, the EU Biotech Directive provides a supplementary means of interpretation for the EPC (Rule 26(1) EPC). Thus, when the compliance of a biotechnological invention with ethical principles has to be assessed, the legal framework is a composite one, in the sense that the EPC provisions should be understood in the light of the EU Biotech Directive, also including considerations which are outside the strict patentability requirements."
• "Human-animal chimeras are not mentioned in Rule 28(1)(a) to (d) EPC, nor in the provision from which this Rule is derived, namely Article 6(2) of the EU Biotech Directive. However, specific forms of human-animal chimeras are mentioned in Recital 38, which relates to the illustrative list of exclusions for reasons of ordre public and morality provided in Article 6(2) of the EU Biotech Directive. Recital 38 includes the following wording:

"...whereas processes, the use of which offend against human dignity, such as processes to produce chimeras from germ cells or totipotent cells of humans and animals, are obviously also excluded from patentability;".

• "Recital 38 does not exclude chimeras as such, but specifically identifies processes to produce chimeras from germ cells or totipotent cells of humans. Since the present invention involves the use of pluripotent cells, which are distinct from totipotent cells and germ cells, it can be said that Recital 38 does not apply directly.
• This sets up the legal puzzle: if the EU legislator intentionally did not wish to exlcude human-animal chimeras in general (and, at the time of drafting, did not think of pluripotent cells, perhaps), what is excluded? Only the recited type of chemiras? Or some intermediate class?
• "The board takes the view that the exclusion of Article 53(a) in conjunction with Rule 28(1) EPC may extend to other chimeras, where the rationale underlying the examples identified in Recital 38 is also applicable to the chimeras concerned. Thus, by means of Rule 26(1) EPC a further special case is added to the non-exhaustive list of Rule 28(1) EPC."
• Rule 26(1): "For European patent applications and patents concerning biotechnological inventions, the relevant provisions of the Convention shall be applied and interpreted in accordance with the provisions of this Chapter. Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions shall be used as a supplementary means of interpretation."
• "the board finds that the reason why the chimeras identified in Recital 38 are regarded as offensive against human dignity is due to concerns that, in chimeras including human germ cells or totipotent cells, these human cells may integrate into the brain and/or develop into germ cells and result in a chimera with human or human-like capabilities. 
•  This reason is straightforward for chimeras including totipotent cells, which in view of their developmental capability to form an entire organism may form a brain with human-like cognitive abilities or human germ cells. 
• The Board finds it 'straightforward', but that may be a case of hindsight in solving a legal problem.
• "However the same reason applies to pluripotent cells, which despite lacking the ability to differentiate into totipotent cells or cells of the placenta, nevertheless have the ability to differentiate into neural cells or germ cells. Thus, if an invention relates to a situation where human cells might integrate into the chimera's brain, potentially giving the chimera human-like cognitive or behavioural capabilities, or into its germ line, potentially giving it the ability to pass on humanised traits, the board considers that the underlying rationale of Recital 38 of the Directive would be relevant and shall be taken into account in examining compliance with Article 53(a) in conjunction with Rule 28(1) EPC."
• "the board does not consider it necessary to refer to the preparatory work to the EU Biotech Directive. Whereas the recourse to the preparatory work is possible as supplementary means of interpretation under Article 32 Vienna Convention, the board finds that in the present circumstances there is no ambiguous or obscure meaning in the wording of the exclusions in Recital 38 which needs to be clarified, nor does the interpretation on account of its object and purpose lead to a result which is manifestly absurd or unreasonable."
• Article 32 Vienna Convention indeed limits the use of the preparatory documents to these two cases, though the EPC travaux are cited more freely by the Boards.
• "With regard to the present case it must therefore be established whether the invention defined in claims 3 to 5 includes embodiments that fall under the scope of Recital 38 [by analogy?], thus contravening the requirements of Article 53(a) EPC in conjunction with Rule 28(1) EPC. Specifically, it must be determined whether the claims define chimeras and methods of producing chimeras including embodiments where human cells participate in the brain or germ cells of the chimera."
• "Document D15 is a scientific article on research into ways of regulating the differentiation of the donor cells into the endodermal organs, in order to address concerns that human cells might be present in the germ line or participate in the brain of chimeras resulting from blastocyst complementation. These ethical concerns are set out prominently in the abstract of the document:"Blastocyst complementation, which exploits the capacity of PSCs to participate in forming chimeras, does not, however, exclude contribution of PSCs to the development of tissues - including neural cells or germ cells - other than those targeted ..."."
• "Even years after the date of filing of the application, these concerns remained undiminished, as evidenced by documents D9 and D10, which were made available to the public in 2019 and 2021 respectively."
• " On the basis of the documents on file and on the balance of probabilities, the board can only conclude that there is no technical reason to dismiss the ethical concerns, raised in the relevant literature, that human cells may be present in the brain or germ cells of a chimera according to the present invention. These concerns are relevant for chimeras resulting from the method defined in claim 5, as well as for the chimeras as defined in claims 3 and 4. This conclusion also takes into account that the method defined in claim 5 has no limitations as regards either the number of human cells injected in step (c) and that claims 3 and 4 do not include any limitations as to the number of human cells or exclude their presence in the brain or germ line."
• The relevant date is the filing date, I understand: "14. The assessment of objections under Article 53(a) EPC, as well as under Rule 28(1) EPC, should be based on the understanding in the technical field at the relevant date of the patent application, although evidence arising after that date may be taken into account, provided it reflects the state of the art at the effective date (see decision T 315/03, Reasons 8.2, 9.5, 9.7 and 10.9)."
• Cf. G 2/08: "Rule 28(c) EPC (formerly Rule 23d(c) EPC) forbids the patenting of claims directed to products which - as described in the application -  at the filing date could be prepared exclusively by a method which necessarily involved the destruction of the human embryos from which the said products are derived, even if the said method is not part of the claims." (not cited in the present decision; and Article 83 EPC might be relevant here).
• "the appellant stressed also the dramatic importance of the present invention in the field of xenotransplantation, potentially the very first step to repair and replacement technology which was previously regarded as pure science fiction. This fact should be balanced against the unsupported ethical concerns raised by the examining division."
• "The board recognises the importance of the present invention. However, for the reasons stated above, balancing tests are irrelevant in the context of the categories of inventions which are excluded from patentability ipso facto. Considerations involving balancing the potential benefits of the invention for humanity/the medical benefit against prejudice to human dignity/animal suffering, are limited to the so-called "real" Article 53(a) EPC objections or to inventions related to the genetic modification of animals within the meaning of Rule 28(1)(d) EPC. Instead, where the legislator wanted to exclude inventions offending life and human dignity as such, there can be no room for manoeuvre (see also G 2/06, Reasons 31)."
  
  
• "since the claims were not drafted to exclude embodiments where human cells are present in the brain and/or germ cells of the chimera (for instance by the inclusion of features based on technologies capable of preventing the presence of human cells in the brain and/or germ cells of the chimera) the board did not have to decide on the patentability of such subject-matter."

• As a comment, if these "technologies capable of preventing the presence of human cells in the brain and/or germ cells of the chimera" are now available and common general knowledge, the Art. 53(a) EPC objection can be addressed with an undisclosed disclaimer (G2/03), most likely, and Article 83 EPC is complied with by the availability of these preventive technologies (and appropriate reference to them in the application as filed).
• 
  
• 
  
• Suppose the preventive technologies also work for the chimeras from germ cells or totipotent cells of humans and animals" are these then patentable (under a dynamic interpretation, perhaps)?

EPO 

The link to the decision can be found after the jump.

https://www.epo.org/en/boards-of-appeal/decisions/t221553eu1

T 1170/20 - Reach through claim and functional definitions

Key points

• Claim 1 is directed to, in translation: "Medium and/or high voltage gas-insulated electrical equipment comprising .... a gas-tight sealed envelope whose interior volume is filled with an electrically insulating gas comprising at least one fluorinated compound whose global warming potential is less than 3500"
• The Board rejects the claim as a reach-through claim. 
• In translation: "The appellant [opponent] argues that the characteristic "an electrically insulating gas containing at least one fluorinated compound with a global warming potential (GWP) of less than 3500" gives the claim a so-called “reach through” character, namely that the claim relates to a chemical compound defined only in functional terms. The Board agrees with the [opponent]."
• "The claim requires an insulating gas in a medium or high voltage gas-insulated electrical apparatus. The skilled person must find among the broad class of fluorinated compounds those having both a GWP of less than 3500 and a suitability for producing an insulating gas in a medium or high voltage apparatus. The argument that any fluorinated compound would be suitable for electrical insulation of a medium or high voltage apparatus does not convince the Board. The applicant rightly argues that significant efforts are being made to replace SF6 as an insulating gas. It is in fact difficult to find other promising solutions"
• The patent mentions classes of gases. "For these classes, a few individual compounds are disclosed as examples [in the patent]. The Board is satisfied that there are fluoroketones suitable for electrical insulation of electrical apparatus as claimed (see documents A3 and A4). However, the rest of these examples are presented without any proof of their suitability. Some of these examples are clearly erroneous, such as "HFO 1336 mzzzM" or "C7F18O", as the respondent itself argues.
• The Board is of the opinion that it is not sufficient to present a few broad classes of fluorinated compounds and a few individual specific examples with a desired GWP without proof that in essence all members of the classes of compounds satisfy all the criteria for suitability as insulating gases for medium or even high voltage switchgear. "

• "the respondent argued that the invention was not aimed at finding all suitable compounds as low GWP insulating gas. On the contrary, an apparatus using such insulating gas was the background against which the invention was made. The current invention aimed at avoiding heat losses by managing the condensate, ensuring that a sufficient amount of insulating gas is in the gas phase." 

• "The Board cannot accept this argument. The requirement of sufficiency of disclosure concerns the invention in its entirety, and not only that part which the applicant or proprietor considers to be the inventive contribution. If any part of the invention defined in the claims cannot be carried out, then that invention may be the subject of an objection for insufficiency of disclosure. Otherwise, speculative patents may have to be granted because their subject-matter relates in part to construction details which can be carried out even though that subject-matter would not be possible in its entirety."

• "contrary to the respondent's claim, the technical field to which a claim relates is irrelevant when it is characterized as being of the "reach-through" type. The essential idea of ​​not allowing claims of this type is explained in the cited section of the Guidelines as follows:  [F-III,9] [Quote from the English Guidelines added, PJL] "A functional definition of a chemical compound ("reach-through" claim) covers all compounds possessing the activity or effect specified in the claim. It would be an undue burden to isolate and characterise all potential compounds (e.g. agonists/antagonists), without any effective pointer to their identity (see F‑III, 1), or to test every known compound and every conceivable future compound for this activity to see if it falls within the scope of the claim. In effect, the applicant is attempting to patent what has not yet been invented, and the fact that the applicant can test for the effect used to define the compounds does not necessarily confer sufficiency on the claim; in fact it constitutes an invitation for the skilled person to perform a research programme (see T 435/91 (Reasons 2.2.1), followed by T 1063/06 (Headnote II)). "

• "This explanation is extended to the present case. The claim covers all compounds having a GWP of less than 3500 and having the function of an insulating gas for medium and/or high voltages. The patent does not contain any clear indication as to their identity, beyond an indication that these compounds contain fluorine. The board pointed out above that the difficulty lies in finding suitable compounds. The respondent simply states and without providing any evidence that a person skilled in the art could find the suitable compounds using only his ordinary skills and given a suitable compound, the GWP could be determined. However, this is exactly the case described in the Guidelines, namely that in reality the respondent is trying to patent what has not yet been invented, and the fact that the effects used to define compounds can be tested does not mean that the claim sufficiently discloses the invention. The claim is in fact an invitation to carry out a search program."

• 
  

EPO 

The link to the decision and an extract of it can be found after the jump.

R 0013/21 - Review of decisions to hold inadmissible

Key points

• The Enlarged Board in translation: "According to the case law of the Enlarged Board of Appeal, discretionary decisions on the admission of new submissions or new requests are only subject to limited review. In the procedure under Article 112a EPC, the only things that can be examined are (i) whether the party was heard on the question of admission and/or (ii) whether there was an error of discretion. The latter examination may at most relate to two aspects, namely whether there was any discretion at all and whether the board also recognised this fact (exceeding or failing to exercise discretion), and whether the exercise of discretion was arbitrary or manifestly unlawful (abuse or misuse of discretion)"
• So, in summary, there are three grounds to challenge a decision under Art. 12 or 13 RPBA to hold a submission inadmissible in a petition for review:
• the party was not heard on the question of admissibility;
• the board had no discretion to hold the submission inadmissible;
• the board's discretionary decision was arbitrary or manifestly unlawful in the sense of abuse or misuse of discretion. (Ausübung des Ermessens willkürlich oder offensichtlich rechtswidrig war (Ermessensmissbrauch bzw. -fehlgebrauch))
• This seems to define a practical framework. It seems similar to, but a bit stricter than, the test of G7/93 r.2.6: "either that the first instance department in its decision has not exercised its discretion in accordance with the right principles [...] or that it has exercised its discretion in an unreasonable way, and has thus exceeded the proper limits of its discretion"
• In the case at hand, the inventive step attack over D7 + common general knowledge was held inadmissible after the novelty attack over D7 in view of common general knowledge was rejected on the merits. A rather strict approach, but the term common general knowledge can sometimes cover a few nuances. 

• The Board considered the MR to be not novel, the added feature of AR-1 to provide novelty, and did not admit the inventive step attack. The Board then maintained the patent according to AR-1 without examining the inventive step requirement.
• The Enlarged Board: "Although the board's approach of considering auxiliary request 1 to be allowable without further substantive examination may appear questionable from the point of view of Article 101(3) EPC (see the Enlarged Board of Appeal's communication of 30 November 2023, points 24-25 for details), the latter requirement and possible violations thereof are, however, irrelevant for the review procedure."
  
  
• The petition for review was filed on  16.07.2021 and rejected by a three-member panel on 25.10.2024.
• I don't know what the reasons for the delay were in this case. The file shows a change in the composition of the panel and a change in the rapporteur in 2023.
• Still, we can only hope the situation will improve soon.

EPO 

The link to the decision and an extract of it can be found after the jump.